Cortechs.ai | New partnership: Quantifying brain volume loss in MS

New partnership: Quantifying brain volume loss in MS

Advanced MS therapeutics combined with the innovative NeuroQuant® software provides invaluable information to neurologists and radiologists.

(SAN DIEGO) April 21, 2015 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis is pleased to announce a partnership agreement with Novartis Pharma AG, a global pharmaceutical company. The companies will collaborate to develop NeuroQuant’s powerful brain volume quantification report targeting the identification, measurement and tracking of brain volume loss in multiple sclerosis patients.

The resulting report enables clinicians to automatically conduct accurate and consistent measurements of the whole brain, left and right thalami and the lateral ventricles out of 3D T1 MRI images. The report is targeting the identification and tracking of neurodegeneration in these sub-cortical structures. This breakthrough solution, which is available both online and as an installed software solution, provides neurologists and radiologists with objective support of brain volume loss and its changes over time and as compared to normative values.

“We’re pleased to partner with Novartis to advance the clinical care and assessment of multiple sclerosis worldwide,” said Guri Stark, Cortechs.ai’ CEO. “We believe this partnership will empower clinicians with objective quantitative data, while continuing NeuroQuant’s growth momentum. This, in-turn furthers our vision to establish NeuroQuant as the standard measurement solution for all brain disorders, including Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury.”

About Cortechs.ai

Cortechs.ai develops and markets cutting-edge brain imaging solutions used by neurologists and radiologists in hundreds of clinics and research centers around the world. CorTechs’ flagship product, NeuroQuant®, is a breakthrough, 510(k) cleared software medical device that makes quantitative analysis of MRI images of the human brain a routine part of clinical practice. As the first FDA cleared and CE marked medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant® brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device. This provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy, multiple sclerosis and traumatic brain injury. Please visit cortechs.ai or www.wholebrainatrophy.com for further information.

###

Media Contact:
Travis Foegler
Phone: +1 (619) 450-9094
Email: Tfoegler@cortechs.ai

More Resources

10/07/2025

Cortechs.ai Expands Partnership with Strategic Radiology to Advance Imaging Innovation Across Private Practices

Cortechs.ai and Strategic Radiology have now broadened their alliance to include Cortechs.ai’s full suite of imaging solutions.

10/06/2025

Clinical Performance of NeuroQuant: Transforming Brain MRI Analysis

NeuroQuant has consistently demonstrated strong clinical performance across multiple conditions, including Alzheimer’s , epilepsy, TBI, and MS.

10/02/2025

WEBINAR: Navigating Category III CPT Codes for Quantitative Imaging

Leveraging Compatible CPT Codes for NeuroQuant and OnQ Prostate

09/29/2025

The Role of NeuroQuant in Supporting Alzheimer’s Disease Care

NeuroQuant equips clinicians and researchers with data that can support earlier recognition of disease, track progression, and evaluate treatment efficacy.

09/16/2025

OnQ Prostate for Focal Therapy

Read how OnQ Prostate supports focal therapy by personalizing prostate cancer care for patients while minimizing the risks associated with it.

09/03/2025

Reimbursement Considerations for OnQ Prostate and Category III CPT Codes 0648T & 0649T

Learn how Cat. III CPT codes 0648T and 0649T apply to OnQ™ Prostate, offering guidance for accurate reporting, reimbursement, and building evidence for coverage
Scroll to Top